Preventing AVF thrombosis: the rationale and design of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study

Ashley Irish, Gursharan Dogra, Trevor A Mori, Elaine Beller, Stephanie R Heritier, Carmel M Hawley, Peter Kerr, Amanda Robertson, Johan B Rosman, Peta-Anne Paul-Brent, Melissa Starfield, Kevan R Polkinghorne, Alan Cass

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)

Abstract

Background: Haemodialysis (HD) is critically dependent on the availability of adequate access to the systemic circulation, ideally via a native arteriovenous fistula (AVF). The Primary failure rate of an AVF ranges between 20a??54 , due to thrombosis or failure of maturation. There remains limited evidence for the use of anti-platelet agents and uncertainty as to choice of agent(s) for the prevention of AVF thrombosis. We present the study protocol for a randomised, double-blind, placebo-controlled, clinical trial examining whether the use of the anti-platelet agents, aspirin and omega-3 fatty acids, either alone or in combination, will effectively reduce the risk of early thrombosis in de novo AVF.
Original languageEnglish
Pages (from-to)1 - 12
Number of pages12
JournalBMC Nephrology
Volume10
DOIs
Publication statusPublished - 2009

Cite this